VitaNova Life Sciences (VNOV) Cash & Equivalents (2017 - 2026)

VitaNova Life Sciences has disclosed Cash & Equivalents across 9 years of filings, most recently posting $1.6 million for Q3 2026.

• Cash & Equivalents for Q3 2026 came in at $1.6 million, up 53.27% year-over-year; the trailing twelve-month figure through Jul 2026 was $1.6 million (up 53.27% YoY), and the FY2026 annual result was $1.6 million, up 104.04% from the prior year.
• Cash & Equivalents for Q3 2026 stood at $1.6 million, roughly flat from $1.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.6 million in Q3 2026 and bottomed at $8728.0 in Q2 2023.
• Average Cash & Equivalents over 5 years is $575050.8, with a median of $405173.0 recorded in 2025.
• The widest annual swing landed in 2023, when Cash & Equivalents plunged 70.18%; it then jumped 7240.02% in 2024.
• Year by year, Cash & Equivalents stood at $36190.0 in 2022, then slumped by 75.88% to $8728.0 in 2023, then soared by 2452.65% to $222795.0 in 2024, then jumped by 465.22% to $1.3 million in 2025, then advanced by 27.39% to $1.6 million in 2026.
• The last three Cash & Equivalents figures came in at $1.6 million (Q3 2026), $1.6 million (Q2 2026), and $1.2 million (Q1 2026), per Business Quant data.